Molecular genetics of lung cancer in people who have never smoked.

[1]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[2]  P. Jänne,et al.  Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Milanowski,et al.  Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Tanoue,et al.  Annual Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses—United States, 1997–2001 , 2007 .

[5]  G. Giaccone,et al.  Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study , 2006, Clinical Cancer Research.

[6]  K. Fong,et al.  Epigenetics of lung cancer , 2006, Respirology (Carlton South. Print).

[7]  H. Koong,et al.  Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Michael J Thun,et al.  Lung cancer death rates in lifelong nonsmokers. , 2006, Journal of the National Cancer Institute.

[9]  R. Wilson,et al.  Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Takayuki Kosaka,et al.  Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Y. Bang,et al.  Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation , 2006, Clinical Cancer Research.

[12]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[13]  A. Gazdar,et al.  Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers , 2006, International journal of cancer.

[14]  J. Luketich,et al.  Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. , 2006, Neoplasia.

[15]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[16]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[17]  Xin Li,et al.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[20]  M. Lübbert,et al.  DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. , 2005, Critical reviews in oncology/hematology.

[21]  P. Hainaut,et al.  TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. , 2005, Cancer research.

[22]  W. Akerley,et al.  Natual history of non-small cell lung cancer in non-smokers , 2005 .

[23]  Y. Yatabe,et al.  EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma , 2005, The American journal of surgical pathology.

[24]  F. Gilliland,et al.  Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers , 2005, International journal of cancer.

[25]  William Pao,et al.  Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Minna,et al.  Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.

[27]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[28]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[29]  Joachim Herz,et al.  Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? , 2004, Trends in molecular medicine.

[30]  J. Rigas,et al.  Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Bepler,et al.  Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. , 2004, Chest.

[32]  U. Gatzemeier,et al.  Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) , 2004 .

[33]  J. Minna,et al.  Dose effect of smoking on aberrant methylation in non‐small cell lung cancers , 2004, International journal of cancer.

[34]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[35]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[36]  William Pao,et al.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Roy S Herbst,et al.  Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  G. Giaccone,et al.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Charles A Powell,et al.  Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. , 2003, The American journal of pathology.

[40]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[41]  F. Gilliland,et al.  Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. , 2003, Cancer research.

[42]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Chih-Yi Chen,et al.  Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. , 2003, The Journal of clinical investigation.

[44]  E. Ma,et al.  Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers , 2003, Cancer.

[45]  Toshihide Tsuda,et al.  The TP53 gene, tobacco exposure, and lung cancer , 2003, Human mutation.

[46]  Avrum Spira,et al.  Gene expression in lung adenocarcinomas of smokers and nonsmokers. , 2003, American journal of respiratory cell and molecular biology.

[47]  J. Minna,et al.  Smoke exposure, histologic type and geography‐related differences in the methylation profiles of non‐small cell lung cancer , 2003, International journal of cancer.

[48]  A. Borczuk,et al.  Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers. , 2003, Lung cancer.

[49]  L. Chung,et al.  Primary adenocarcinomas of the lung in nonsmokers show a distinct pattern of allelic imbalance. , 2002, Cancer research.

[50]  L. Liotta,et al.  Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. , 2002, Cancer research.

[51]  L. Mao.  Molecular abnormalities in lung carcinogenesis and their potential clinical implications. , 2001, Lung cancer.

[52]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Sidransky,et al.  Cigarette smoking is strongly associated with mutation of the K‐ras gene in patients with primary adenocarcinoma of the lung , 2001, Cancer.

[55]  C. Harris,et al.  p53 and K-ras mutations in lung cancers from former and never-smoking women. , 2001, Cancer research.

[56]  John K. Wiencke,et al.  p16INK4a and Histology-specific Methylation of CpG Islands by Exposure to Tobacco Smoke in Non-Small Cell Lung Cancer , 2001 .

[57]  P. Hainaut,et al.  Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. , 2001, Carcinogenesis.

[58]  S. Piantadosi,et al.  Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. , 2001, Cancer research.

[59]  Y. Yamashita,et al.  K-ras gene mutations in non-small cell lung cancer in Japanese. , 2000, Oncology reports.

[60]  G. Pershagen,et al.  p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. , 2000, Cancer research.

[61]  M. Tang,et al.  Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. , 2000, Journal of the National Cancer Institute.

[62]  J. Luketich,et al.  Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[63]  P. Hainaut,et al.  A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. , 1998, Environmental health perspectives.

[64]  J. Minna,et al.  p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. , 1998, British Journal of Cancer.

[65]  Chih-Yi Chen,et al.  Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome , 1998, Journal of Cancer Research and Clinical Oncology.

[66]  J. Siegfried,et al.  Prognostic value of specific KRAS mutations in lung adenocarcinomas. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[67]  K. Kondo,et al.  A dose‐response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients , 1996, Journal of surgical oncology.

[68]  R. Ueda,et al.  p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. , 1992, Cancer research.

[69]  S. Rodenhuis,et al.  Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. , 1991, Journal of the National Cancer Institute.

[70]  J H Ho,et al.  Worldwide epidemiological patterns of lung cancer in nonsmokers. , 1990, International journal of epidemiology.